Creating vaccines against a virus that may or may not circulate, depending on its antigenic configuration, is, of course, a gamble and a financial risk.
It isn't easy to find meaningful clinical outcomes when you cannot realistically trial the vaccine(s). So what is the problem? The problem lies in the refusal of regulators, decision-makers, pharma, and…